UBS raises target for Vertex Pharmaceuticals stock to USD 615

Published on 10/07/2026 at 14:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharmaceuticals stock costs EUR 452.28 on October 7, 2026 versus EUR 446.10. Second-quarter 2026 revenue rose 12.00 percent to USD 3.33 billion.

Flatlay-Anordnung mit Zertifikat, ISIN-Karte, Pipette, Fläschchen und Stethoskop — Vertex Pharma US92532F1003 präsentiert eine Flatlay-Anordnung mit Aktienzertifikat, ISIN-Karte und typischen Laborutensilien, Illustration mit AI erstellt.

Vertex Pharmaceuticals (ISIN US92532F1003) was trading at EUR 452.28 at Lang & Schwarz on October 7, 2026 at 2:47 p.m. CEST, plus 1.39 percent versus the prior close of EUR 446.10. According to Investing.com on September 28, 2026, UBS raised its target for Vertex Pharmaceuticals from USD 585 to USD 615 and maintained a Buy rating.

Kidney drug data supports target

The analyst action followed positive inaxaplin data in APOL1-mediated kidney disease. In the modest-proteinuria cohort, urine albumin to creatinine ratio fell 42.70 percent from baseline at Week 13, while the type 2 diabetes cohort delivered a 17.30 percent reduction.

Business Wire reported on September 22, 2026, that Vertex completed enrollment in the Phase 2/3 AMPLITUDE trial and remains on track for interim data in early 2027. The results expand the pipeline beyond cystic fibrosis, but approval still depends on later clinical and regulatory milestones.

Revenue growth remains the anchor

Vertex generated USD 3.33 billion of revenue in the second quarter of 2026, a 12.00 percent increase from the year-earlier period, while GAAP net income reached USD 1.10 billion. The quarter also produced diluted earnings per share of USD 4.31.

According to Ticker Scout, Vertex raised its full-year 2026 revenue guidance to USD 13.10 billion to USD 13.20 billion from USD 12.95 billion to USD 13.10 billion. That range excludes the pending Crinetics acquisition, leaving deal completion and integration as material variables for the outlook.

Stock holds a wide valuation range

Vertex had a market capitalization of USD 127.5 billion as of October 6, 2026. Its primary Nasdaq listing covered a 52-week range of USD 402.58 to USD 560.25, putting the Lang & Schwarz euro quote below the dollar-denominated high without mixing the two currencies.

The next scheduled earnings date is November 2, 2026, according to Nasdaq. For investors, the near-term test is whether the revenue trajectory and pipeline progress can support the higher analyst target while Vertex funds its acquisition plans.

Vertex stock trades above its prior close

At Lang & Schwarz, Vertex Pharmaceuticals was trading at EUR 452.28 on October 7, 2026 at 2:47 p.m. CEST, plus 1.39 percent versus the prior close of EUR 446.10. The further course of trading is shown by the continuously updated real-time quote of Vertex Pharmaceuticals stock.